Read by QxMD icon Read

Hodgkin lymphom

Mario F Scaglioni, Semra Uyulmaz
Lymphedema most commonly occurs after cancer treatment and can affect limbs and genitalia. Genital lymphedema (GL) is a rare condition and can be disabling psychologically and physically. It often occurs along with lower extremity lymphedema (LEL). Conservative and physiologic reconstructive surgery such as lymphaticovenous anastomosis (LVA) offer good treatment options for LEL. GL however remains a reconstructive dilemma. The most effective surgical therapies in advanced GL are still debulking procedures in properly selected patients...
May 2, 2018: Microsurgery
Raihane Ben Lakhal, Sondos Hdiji, Sami Zriba, Amina Mokrani, Mohamed Adnen Laatiri, Yossra BenYoussef, Faten Ezzaier, Nabil Toumi, Salwa Ladeb, Hanen BenSalah, Sameh Tebra, Hatem Frikha, Taha Messai, Jamel Daoued, Noureddine Bouaouina, Monji Maalej, Mounir Frikha, Tarek BenOthmen, Slim BenAhmed, Abderrahim Khelif, Fehmi Msaddek, Amel Mezlini, Moez Elloumi, Balkis Meddeb
OBJECTIVE: In Tunisia, the management of Adult Hodgkin's Lymphoma (HL) has been standardized since 1999. We propose in this study to report the therapeutic results of the national protocol of adult HL treatment (MDH2008). PATIENTS AND METHODS: Our study is prospective multicenter interesting 444 patients followed for HL between July 2008 and June 2013 and treated according to the MDH2008 protocol. The median age of our patients was 30 years. B symptoms were present in 62...
April 27, 2018: Bulletin du Cancer
Christophe Fermé, José Thomas, Pauline Brice, Olivier Casasnovas, Andrej Vranovsky, Serge Bologna, Pieternella J Lugtenburg, Réda Bouabdallah, Patrice Carde, Catherine Sebban, Houchingue Eghbali, Gilles Salles, Gustaaf W van Imhoff, Antoine Thyss, Evert M Noordijk, Oumédaly Reman, Marnix L M Lybeert, Maud Janvier, Michele Spina, Bruno Audhuy, John M M Raemaekers, Richard Delarue, Bruno Anglaret, Okke de Weerdt, Zora Marjanovic, Robbert J H A Tersteeg, Daphne de Jong, Josette Brière, Michel Henry-Amar
PURPOSE: For early-stage Hodgkin lymphoma (HL), optimal chemotherapy regimen and the number of cycles to be delivered remain to settle down. The H9-U trial compared three modalities of chemotherapy followed by involved-field radiotherapy (IFRT) in patients with stage I-II HL and risk factors (NCT00005584). PATIENTS AND METHODS: Patients aged 15-70 years with untreated supradiaphragmatic HL with at least one risk factor (age ≥ 50, involvement of 4-5 nodal areas, mediastinum/thoracic ratio ≥ 0...
August 2017: European Journal of Cancer
Andrew Davies, Francesco Merli, Biljana Mihaljević, Santiago Mercadal, Noppadol Siritanaratkul, Philippe Solal-Céligny, Axel Boehnke, Claude Berge, Magali Genevray, Artem Zharkov, Mark Dixon, Michael Brewster, Martin Barrett, David MacDonald
BACKGROUND: Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5-6 h. A subcutaneous formulation could reduce patients' treatment burden and improve resource utilisation in health care. We aimed to show the pharmacokinetic non-inferiority of subcutaneous rituximab to intravenous rituximab in follicular lymphoma and to provide efficacy and safety data. METHODS: SABRINA is a two-stage, randomised, open-label phase 3 study at 113 centres in 30 countries...
June 2017: Lancet Haematology
Nirav Thacker, Sameer Bakhshi, Girish Chinnaswamy, Tushar Vora, Maya Prasad, Deepak Bansal, Sandeep Agarwala, Gauri Kapoor, Venkatraman Radhakrishnan, Siddharth Laskar, Tanvir Kaur, G K Rath, Rupinder Singh Dhaliwal, Brijesh Arora
Hitherto poor outcomes, paucity of data and heterogeneity in International approach to Pediatric NHL (Non-Hodgkin Lymphoma) prompted the need for guidelines for Indian population with vast variability in access, affordability and infrastructure across the country. These guidelines are based on consensus among the experts and best available evidence applicable to Indian setting. Evaluation of NHL should consist of easily doable and rapid tissue diagnosis (biopsy or flow cytometry of peripheral blood/malignant effusions), St Jude/IPNHLSS (International Pediatric Non-Hodgkin Lymphoma Staging System) and risk grouping with CSF (Cerebro-spinal fluid), bone marrow, whole body imaging [CECT (Contrast enhanced computerized tomography) ± MRI (Magnetic resonance imaging)] and blood investigations for LDH (Lactate dehydrogenase), TLS (Tumor lysis syndrome) and organ functions...
May 2017: Indian Journal of Pediatrics
Maja V Maraldo, Francesco Giusti, Ivan R Vogelius, Michael Lundemann, Marleen A E van der Kaaij, Safaa Ramadan, Bart Meulemans, Michel Henry-Amar, Berthe M P Aleman, John Raemaekers, Paul Meijnders, Elisabeth C Moser, Hanneke C Kluin-Nelemans, Pierre Feugier, Olivier Casasnovas, Catherine Fortpied, Lena Specht
BACKGROUND: Cardiovascular disease after treatment is an important concern in cancer survivors. However, knowledge of cardiotoxicity is limited by the retrospective nature of data, which often does not contain details of treatment exposure. To facilitate individual risk counselling of patients, we aimed to quantify the effect of anthracyclines, vinca-alkaloids, and radiotherapy on the risk of cardiovascular disease in patients treated for Hodgkin's lymphoma. METHODS: In 2009-10, a Life Situation Questionnaire (LSQ) was distributed to patients by mail to assess late-onset effects of Hodgkin's lymphoma treatment in patients who were included in nine successive European Organisation for Research and Treatment of Cancer (EORTC) and the Groupe d'Etude des Lymphomes de l'Adulte (GELA, now renamed LYSA) randomised trials between 1964 and 2004...
November 2015: Lancet Haematology
Mathias Rummel, Ulrich Kaiser, Christina Balser, Martina Stauch, Wolfram Brugger, Manfred Welslau, Norbert Niederle, Christoph Losem, Hans-Peter Boeck, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, Lars Hahn, Julia Vereshchagina, Frank Kauff, Wolfgang Blau, Axel Hinke, Juergen Barth
BACKGROUND: Fludarabine-based chemoimmunotherapy with rituximab is frequently used in patients with indolent and mantle-cell lymphomas who relapse after alkylating chemotherapy. We aimed to compare the efficacy and safety of rituximab with bendamustine or fludarabine in patients with relapsed, indolent, non-Hodgkin lymphoma and mantle-cell lymphoma. METHODS: For this randomised, non-inferiority, open-label, phase 3 trial, we recruited patients from 55 centres in Germany, who were subsequently randomised centrally according to prespecified randomisation lists with permuted blocks of randomly variable block size to rituximab (375 mg/m(2), day 1) plus either bendamustine (90 mg/m(2), days 1 and 2) or fludarabine (25 mg/m(2), days 1-3) every 28 days for a maximum of six 28-day cycles...
January 2016: Lancet Oncology
Gandhi Damaj, Sarah Ivanoff, Diane Coso, Loïc Ysaebert, Sylvain Choquet, Caroline Houillier, Anne Parcelier, Wajed Abarah, Zora Marjanovic, Rémy Gressin, Reda Garidi, Momar Diouf, Anne-Claire Gac, Jehan Dupuis, Xavier Troussard, Franck Morschhauseur, Hervé Ghesquières, Carole Soussain
The purpose of our study is to determine the outcome of patients with systemic non-Hodgkin lymphoma presenting with neurologic localization at diagnosis, as well as the impact of consolidation in terms of high-dose therapy followed by autologous stem cell transplantation. Newly diagnosed non-Hodgkin lymphoma patients with concomitant systemic and neurological involvement at diagnosis were included in this study. Sixty patients (37 males; 25 females) were included. Median age was 61 years (23-85 years). Histological subtype was mainly diffuse large B-cell lymphoma (n = 54; 90%)...
September 2015: Haematologica
M A E van der Kaaij, J van Echten-Arends, N Heutte, P Meijnders, E Abeilard-Lemoisson, M Spina, E C Moser, A Allgeier, B Meulemans, P J Lugtenburg, B M P Aleman, E M Noordijk, C Fermé, J Thomas, A Stamatoullas, C Fruchart, H Eghbali, P Brice, W G J M Smit, C Sebban, J K Doorduijn, J M Roesink, I Gaillard, B Coiffier, M L M Lybeert, O Casasnovas, M André, J M M Raemaekers, M Henry-Amar, J C Kluin-Nelemans
STUDY QUESTION: How does the successful cryopreservation of semen affect the odds of post-treatment fatherhood among Hodgkin lymphoma (HL) survivors? SUMMARY ANSWER: Among 334 survivors who wanted to have children, the availability of cryopreserved semen doubled the odds of post-treatment fatherhood. WHAT IS KNOWN ALREADY: Cryopreservation of semen is the easiest, safest and most accessible way to safeguard fertility in male patients facing cancer treatment...
March 2014: Human Reproduction
Mary Gerrard, Ian M Waxman, Richard Sposto, Anne Auperin, Sherrie L Perkins, Stanton Goldman, Lauren Harrison, Ross Pinkerton, Keith McCarthy, Martine Raphael, Catherine Patte, Mitchell S Cairo
Mediastinal large B-cell lymphoma (MLBL) represents 2% of mature B-cell non-Hodgkin lymphoma in patients ≤ 18 years of age. We analyzed data from childhood and adolescent patients with stage III MLBL (n = 42) and non-MLBL DLBCL (n = 69) treated with Group B therapy in the French-American-British/Lymphome Malins de Burkitt (FAB/LMB) 96 study. MLBL patients had a male/female 26/16; median age, 15.7 years (range, 12.5-19.7); and LDH < 2 versus ≥ 2 × the upper limit of normal, 23:19. Six MLBL patients (14%) had < a 20% response to initial COP (cyclophosphamide, vincristine, and prednisone) therapy...
January 10, 2013: Blood
A Delarue, C Bergeron, F Mechinaud-Lacroix, C Coze, M Raphael, C Patte, Pour le Comité Lymphome de la Sfce
A. Delarue, C. Bergeron, F. Mechinaud-Lacroix, C. Coze, M. Raphael, C. Patte, pour le « Comité Lymphome » de la SFCE Over the past two decades, dramatic improvements in the treatment of children with Non-Hodgkin's Lymphoma have led to cure rates close to 90%, even in advanced-stage disease. The most frequent localization is abdominal, where Burkitt or Burkitt-like subtypes are predominant. Initial management often occurs in the setting of a urgent surgical intervention where multiple complications may gravely threaten prognosis within days or even hours...
October 2008: Journal de Chirurgie
Marleen A E van der Kaaij, Natacha Heutte, Paul Meijnders, Edwige Abeilard-Lemoisson, Michele Spina, Elizabeth C Moser, Anouk Allgeier, Bart Meulemans, Arnold H M Simons, Pieternella J Lugtenburg, Berthe M P Aleman, Evert M Noordijk, Christophe Fermé, José Thomas, Aspasia Stamatoullas, Christophe Fruchart, Pauline Brice, Isabelle Gaillard, Serge Bologna, Francisca Ong, Houchingue Eghbali, Jeanette K Doorduijn, Franck Morschhauser, Catherine Sebban, Judith M Roesink, Marie Bouteloup, Achiel Van Hoof, John M M Raemaekers, Michel Henry-Amar, Hanneke C Kluin-Nelemans
PURPOSE: In this large cohort of Hodgkin's lymphoma survivors with long follow-up, we estimated the impact of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, including safety of nonalkylating chemotherapy and dose-response relationships for alkylating chemotherapy and age at treatment. PATIENTS AND METHODS: The Life Situation Questionnaire was sent to 1,700 women treated in European Organisation for Research and Treatment of Cancer and Groupe d'Étude des Lymphomes de l'Adulte trials between 1964 and 2004...
January 20, 2012: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
C Pinkwart, M Stiefel, C Mauz-Körholz, D Körholz
A 16,5 year old female adolescent was diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL), presenting bilateral inguinal and right iliac lymphadenopathy accompanied by B-symptoms. The patient was due to treatment according to the German Interim Guidelines of HD 2002-Pilot Study with 2x OPPA (vincristine, adriamycine, prednisone, procarbacine) and 2x COPP (cyclophosphamide, vincristine, prednisone, procarbazine) and radiotherapy. After 2x OPPA the patient presented a severe episode of a presumably prednisone-induced acute psychosis with need for psychiatric treatment and change of therapy regimen...
November 2011: Klinische Pädiatrie
Bruce Shiramizu, Stanton Goldman, Ian Kusao, Melissa Agsalda, James Lynch, Lynette Smith, Lauren Harrison, Erin Morris, Thomas G Gross, Warren Sanger, Sherrie Perkins, Mitchell S Cairo
Children/adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL) have an excellent prognosis but relapses still occur. While chromosomal aberrations and/or clonal immunoglobulin (Ig) gene rearrangements may indicate risk of failure, a more universal approach was developed to detect minimal disease (MD). Children/adolescents with intermediate-risk B-NHL were treated with French-British-American/Lymphome Malins de Burkitt 96 (FAB/LMB96) B4 modified chemotherapy and rituximab. Specimens from diagnosis, end of induction (EOI), and end of therapy (EOT) were assayed for MD...
June 2011: British Journal of Haematology
Ranjana H Advani, Richard T Hoppe, Lauren S Maeda, David M Baer, Joseph Mason, Saul A Rosenberg, Sandra J Horning
PURPOSE: In the United States, early-stage Hodgkin's lymphoma (HL) is defined as asymptomatic stage I/II non-bulky disease. European groups stratify patients to more intense treatment by considering additional unfavorable factors, such as age, number of nodal sites, sedimentation rate, extranodal disease, and elements of the international prognostic score for advanced HL. We sought to determine the prognostic significance of these factors in patients with early-stage disease treated at Stanford University Medical Center...
December 1, 2011: International Journal of Radiation Oncology, Biology, Physics
Nozomi Niitsu
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting for approximately 25-30% of all new patients. Rituximab, a genetically engineered chimeric monoclonal antibody that specifically binds to CD20, is the first monoclonal antibody approved for the treatment of B-cell lymphoma. Rituximab significantly improves treatment outcome in DLBCL. A large-phase III study demonstrated improved overall survival (OS) in patients with DLBCL treated with R-CHOP therapy. The Groupe d'Etude des Lymphomes de l'Adulte (GELA), Eastern Cooperative Oncology Group (ECOG) and German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) studies designed for patients older than 60 years have clearly shown prolonged event-free survival (EFS) and OS among patients who received rituximab and chemotherapy...
September 2010: International Journal of Hematology
L Ia Timen, A M Kovrigina, A G Shertsinger, S B Zhigalova, B Z Chikunova, A E Markarov, E V Fedotov, P I Nazar'ev
Clinical supervision diffuse large B-cell lymphoma of the stomach at the patient of young age is presented. Difficulties of the differential diagnostics of lymphom have been caused by macroscopical polyphormism. With the purpose of verification of disease are used the chromoendoscopy and immunohistochemical research.
2010: Experimental & Clinical Gastroenterology
Franck Morschhauser, Nicolas Mounier, Catherine Sebban, Pauline Brice, Phillippe Solal-Celigny, Herve Tilly, Pierre Feugier, Christophe Fermé, Marie Christine Copin, Thierry Lamy
BACKGROUND: This phase 2 trial was undertaken to evaluate the efficacy and safety of rituximab combined with intravenous fludarabine and mitoxantrone (R-FM) for patients with recurrent/refractory follicular lymphoma who had high tumor burden according to Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria. METHODS: Fifty patients were enrolled who had received a maximum of 2 previous regimens, including 1 cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/CHOP-like regimen but no previous exposure to rituximab, fludarabine, or mitoxantrone...
September 15, 2010: Cancer
Natacha Heutte, Henning H Flechtner, Nicolas Mounier, Wilhelmina A M Mellink, Jacobus H Meerwaldt, Houchingue Eghbali, Mars B van't Veer, Evert M Noordijk, Johanna C Kluin-Nelemans, Elzbieta Lampka, José Thomas, Pieternella J Lugtenburg, Luisa Viterbo, Patrice Carde, Anton Hagenbeek, Richard Wm van der Maazen, Wilma G J M Smit, Pauline Brice, Marinus van Marwijk Kooy, Johanna W Baars, Philip Poortmans, Umberto Tirelli, Onno C Leeksma, Radka Tomsic, Pierre Feugier, Gilles Salles, Jean Gabarre, Marie José Kersten, Eric Van Den Neste, Geert-Jan M Creemers, Isabelle Gaillard, Paul Meijnders, Gérard Tertian, Oumédaly Reman, Hein P Muller, Jacques Troncy, Michel Blanc, Wilfried Schroyens, Paul J Voogt, Pierre Wijermans, Chantal Rieux, Christophe Fermé, Michel Henry-Amar
BACKGROUND: Little is known about the longitudinal course of health-related quality of life (HRQoL) in patients with Hodgkin's lymphoma during their post-treatment follow-up and re-adaptation to normal life. We report on the HRQoL of patients treated in the randomised H8 trial of the European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). We aimed to assess HRQoL and fatigue following treatment, to analyse relations with treatment, and to identify factors that predict persistent fatigue...
December 2009: Lancet Oncology
Michel Meignan, Andrea Gallamini, Michel Meignan, Andrea Gallamini, Corinne Haioun
An international workshop, under the auspices of Group d'Etude des Lymphomes de l'Adulte (GELA) took place in Deauville, France, in April 3-4, 2009. The European experts with a published or personal experience on interim-PET in lymphoma were invited to the meeting. The aim of the workshop was twofold: (1) to reach a consensus on simple, reproducible criteria for interim-PET interpretation in Hodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL), and (2) to launch two or more international validation studies, in an attempt to validate these rules...
August 2009: Leukemia & Lymphoma
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"